तुलना करने के लिए मीट्रिक्स | 358570 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध358570पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −13.7x | −6.3x | −0.4x | |
PEG अनुपात | −0.25 | −0.19 | 0.00 | |
क़ीमत/बुक | 4.4x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 84.6x | 6.8x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 50.9% | 56.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 22.4% | 9.1% | अनलॉक करें |
GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101/GI-102, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; GI-108, an metabolic immunotherapy oncology agent; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The company was founded in 2017 and is based in Seoul, South Korea.